keyword
MENU ▼
Read by QxMD icon Read
search

"RSV vaccine"

keyword
https://www.readbyqxmd.com/read/27918420/synthetic-biodegradable-microparticle-and-nanoparticle-vaccines-against-the-respiratory-syncytial-virus
#1
REVIEW
Patricia A Jorquera, Ralph A Tripp
Synthetic biodegradable microparticle and nanoparticle platform technology provides the opportunity to design particles varying in composition, size, shape and surface properties for application in vaccine development. The use of particle vaccine formulations allows improvement of antigen stability and immunogenicity while allowing targeted delivery and slow release. This technology has been design to develop novel vaccines against the respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infection in infants...
December 2, 2016: Vaccines
https://www.readbyqxmd.com/read/27914740/predicting-the-relative-impacts-of-maternal-and-neonatal-respiratory-syncytial-virus-rsv-vaccine-target-product-profiles-a-consensus-modelling-approach
#2
Wirichada Pan-Ngum, Timothy Kinyanjui, Moses Kiti, Sylvia Taylor, Jean-François Toussaint, Sompob Saralamba, Thierry Van Effelterre, D James Nokes, Lisa J White
BACKGROUND: Respiratory syncytial virus (RSV) is the major viral cause of infant and childhood lower respiratory tract disease worldwide. Defining the optimal target product profile (TPP) is complicated due to a wide range of possible vaccine properties, modalities and an incomplete understanding of the mechanism of natural immunity. We report consensus population level impact projections based on two mathematical models applied to a low income setting. METHOD: Two structurally distinct age-specific deterministic compartmental models reflecting uncertainty associated with the natural history of infection and the mechanism by which immunity is acquired and lost were constructed...
November 28, 2016: Vaccine
https://www.readbyqxmd.com/read/27903593/respiratory-syncytial-virus-infection-detection-and-new-options-for-prevention-and-treatment
#3
REVIEW
Cameron Griffiths, Steven J Drews, David J Marchant
Respiratory syncytial virus (RSV) infection is a significant cause of hospitalization of children in North America and one of the leading causes of death of infants less than 1 year of age worldwide, second only to malaria. Despite its global impact on human health, there are relatively few therapeutic options available to prevent or treat RSV infection. Paradoxically, there is a very large volume of information that is constantly being refined on RSV replication, the mechanisms of RSV-induced pathology, and community transmission...
January 2017: Clinical Microbiology Reviews
https://www.readbyqxmd.com/read/27895172/pulmonary-dendritic-cell-subsets-shape-the-respiratory-syncytial-virus-specific-cd8-t-cell-immunodominance-hierarchy-in-neonates
#4
Allison M W Malloy, Tracy J Ruckwardt, Kaitlyn M Morabito, Annie W Lau-Kilby, Barney S Graham
Young infants are generally more susceptible to viral infections and experience more severe disease than do adults. CD8(+) T cells are important for viral clearance, and although often ineffective in neonates they can be protective when adequately stimulated. Using a murine CB6F1/J hybrid model of respiratory syncytial virus (RSV) infection, we previously demonstrated that the CD8(+) T cell immunodominance hierarchy to two RSV-derived epitopes, K(d)M282-90 and D(b)M187-195, was determined by the age at infection...
November 28, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27889256/controlled-human-infection-with-rsv-the-opportunities-of-experimental-challenge
#5
Maximillian S Habibi, Christopher Chiu
Despite the recent explosion in RSV vaccine development, there remain substantial hurdles to overcome before licensing of effective vaccines will allow widespread use, particularly in high-risk populations. Incomplete understanding of mechanisms and correlates of protection against RSV mean that, for the time being, successful RSV vaccines must directly demonstrate efficacy, which necessitates large and costly clinical trials in naturally infected patients. To mitigate the risks inherent in progressing to these late-stage trials, experimental human RSV infection studies have recently been re-established, representing the interface between pre-clinical models and observational studies of patients...
November 23, 2016: Vaccine
https://www.readbyqxmd.com/read/27856770/update-from-the-advisory-committee-on-immunization-practices
#6
Jennifer E Schuster, Sean O'Leary, David W Kimberlin
The Advisory Committee on Immunization Practices (ACIP) consists of medical and public health experts who develop recommendations on vaccine use in the United States. The ACIP meets 3 times per year, and members and Centers for Disease Control (CDC) staff present findings and discuss vaccine research, vaccine effectiveness (VE) and safety, clinical trial results, and labeling/package insert information. Outbreaks of vaccine-preventable diseases and vaccine shortages are also discussed. Nonvoting representatives from the American Academy of Pediatrics and the Pediatric Infectious Diseases Society are present...
December 2016: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/27851799/absence-of-association-between-cord-specific-antibody-levels-and-severe-respiratory-syncytial-virus-rsv-disease-in-early-infants-a-case-control-study-from-coastal-kenya
#7
Joyce Uchi Nyiro, Charles Jumba Sande, Martin Mutunga, Patience Kerubo Kiyuka, Patrick Kioo Munywoki, John Anthony G Scott, David James Nokes
BACKGROUND: The target group for severe respiratory syncytial virus (RSV) disease prevention is infants under 6 months of age. Vaccine boosting of antibody titres in pregnant mothers could protect these young infants from severe respiratory syncytial virus (RSV) associated disease. Quantifying protective levels of RSV-specific maternal antibody at birth would inform vaccine development. METHODS: A case control study nested in a birth cohort (2002-07) was conducted in Kilifi, Kenya; where 30 hospitalised cases of RSV-associated severe disease were matched to 60 controls...
2016: PloS One
https://www.readbyqxmd.com/read/27799521/vaccination-strategies-against-respiratory-syncytial-virus
#8
Dan Yamin, Forrest K Jones, John P DeVincenzo, Shai Gertler, Oren Kobiler, Jeffrey P Townsend, Alison P Galvani
Respiratory syncytial virus (RSV) is the most common cause of US infant hospitalization. Additionally, RSV is responsible for 10,000 deaths annually among the elderly across the United States, and accounts for nearly as many hospitalizations as influenza. Currently, several RSV vaccine candidates are under development to target different age groups. To evaluate the potential effectiveness of age-specific vaccination strategies in averting RSV incidence, we developed a transmission model that integrates data on daily infectious viral load and changes of behavior associated with RSV symptoms...
November 15, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27771388/intranasal-treatment-with-a-novel-immunomodulator-mediates-innate-immune-protection-against-lethal-pneumonia-virus-of-mice
#9
Elisa C Martinez, Ravendra Garg, Pratima Shrivastava, Susantha Gomis, Sylvia van Drunen Littel-van den Hurk
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in infants and young children. There are no licensed RSV vaccines available, and the few treatment options for high-risk individuals are either extremely costly or cause severe side effects and toxicity. Immunomodulation mediated by a novel formulation consisting of the toll-like receptor 3 agonist poly(I:C), an innate defense regulator peptide and a polyphosphazene (P-I-P) was evaluated in the context of lethal infection with pneumonia virus of mice (PVM)...
October 19, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27750448/respiratory-syncytial-virus-vaccines-an-update-on-those-in-the-immediate-pipeline
#10
Susanna Esposito, Giada Di Pietro
Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development...
October 18, 2016: Future Microbiology
https://www.readbyqxmd.com/read/27738052/clinical-and-socioeconomic-burden-of-respiratory-syncytial-virus-infection-in-children
#11
Terho Heikkinen, Emilia Ojala, Matti Waris
BACKGROUND:  Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on the full impact of RSV infection on outpatient children. METHODS:  We analyzed the burden of RSV illness in a prospective cohort study of children aged ≤13 years during 2 consecutive respiratory seasons in Turku, Finland (2231 child-seasons of follow-up). We examined the children and obtained nasal swabs for the detection of RSV during each respiratory illness...
October 12, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27721128/a-single-intranasal-immunization-with-a-subunit-vaccine-formulation-induces-higher-mucosal-iga-production-than-live-respiratory-syncytial-virus
#12
Ravendra Garg, Michael Theaker, Elisa C Martinez, Sylvia van Drunen Littel-van den Hurk
Respiratory syncytial virus (RSV) causes serious respiratory illness in infants and elderly. RSV infection induces short-lived immunity, which leaves people prone to re-infection. In contrast, the RSV fusion (F) protein formulated with a novel adjuvant (∆F/TriAdj) elicits long term protective immunity. A comparison of RSV-immunized mice to mice vaccinated with a single dose of ∆F/TriAdj showed no difference in IgG1 and IgG2a production; however, local IgA secreting memory B cell development and B cell IgA production were significantly lower in RSV vaccinated mice than in ∆F/TriAdj-immunized mice...
October 6, 2016: Virology
https://www.readbyqxmd.com/read/27720994/non-invasive-epicutaneous-vaccine-against-respiratory-syncytial-virus-preclinical-proof-of-concept
#13
Pierre-Louis Hervé, Delphyne Descamps, Charlotte Deloizy, Véronique Dhelft, Daphné Laubreton, Edwige Bouguyon, Abdelhak Boukadiri, Catherine Dubuquoy, Thibaut Larcher, Pierre-Henri Benhamou, Jean-François Eléouët, Nicolas Bertho, Lucie Mondoulet, Sabine Riffault
To put a Respiratory Syncytial Virus (RSV) vaccine onto the market, new vaccination strategies combining scientific and technical innovations need to be explored. Such a vaccine would also need to be adapted to the vaccination of young children that are the principal victims of acute RSV infection. In the present project, we describe the development and the preclinical evaluation of an original epicutaneous RSV vaccine that combines two technologies: Viaskin® epicutaneous patches as a delivery platform and RSV N-nanorings (N) as a subunit antigen...
October 6, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27689356/potential-cost-effectiveness-of-rsv-vaccination-of-infants-and-pregnant-women-in-turkey-an-illustration-based-on-bursa-data
#14
Koen B Pouwels, Sefika E Bozdemir, Selen Yegenoglu, Solmaz Celebi, E David McIntosh, Serhat Unal, Maarten J Postma, Mustafa Hacimustafaoglu
BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed...
2016: PloS One
https://www.readbyqxmd.com/read/27688078/dna-vaccine-encoding-central-conserved-region-of-g-protein-induces-th1-predominant-immune-response-and-protection-from-rsv-infection-in-mice
#15
Ying Hua, Yue-Ying Jiao, Yao Ma, Xiang-Lei Peng, Yuan-Hui Fu, Yan-Peng Zheng, Tao Hong, Jin-Sheng He
Human respiratory syncytial virus (RSV) can cause serious infection in the lower respiratory tract, especially in infants, young children, the elderly and the immunocompromised population worldwide. Previous study demonstrated the polypeptide (amino acids 148-198) of RSV attachment (G) glycoprotein, corresponding to the central conserved region and encompassing CX3C chemokine motif, could induce antibodies and protection from RSV challenge in mice [1,2]. In this study, we evaluated the immune efficacy of the recombinant DNA vaccine of pVAX1/3G148-198 encoding RSV G protein polypeptide...
September 26, 2016: Immunology Letters
https://www.readbyqxmd.com/read/27590768/analysis-of-immune-epitopes-of-respiratory-syncytial-virus-for-designing-of-vectored-vaccines-based-on-influenza-virus-platform
#16
I N Isakova-Sivak, D A Korenkov, E A Fedorova, T S Tretiak, V A Matyushenko, T A Smolonogina, L G Rudenko
The immunoepitope database was used for analysis of experimentally detected epitopes of the respiratory syncytial virus (RSV) proteins and for selection of the epitope combinations for subsequent designing of recombinant vectored anti-RSV vaccines based on attenuated influenza viruses. Three cassettes containing the most promising B- and T-cell RSV epitopes were selected: peptide F (243-294) supporting the formation of humoral immunity in animals; fragment M2-1 (70-101+114-146) containing two MHC I epitopes (82-90 and 127-135); and MHC II-epitope (51-66)...
August 2016: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/27566900/challenges-and-opportunities-in-rsv-vaccine-development-meeting-report-from-fda-nih-workshop
#17
Jeffrey N Roberts, Barney S Graham, Ruth A Karron, Flor M Munoz, Ann R Falsey, Larry J Anderson, V Marshall, Sonnie Kim, Judy A Beeler
Respiratory syncytial virus (RSV) is the most common cause of serious acute lower respiratory illness in infants and young children and a significant cause of disease burden in the elderly and immunocompromised. There are no licensed RSV vaccines to address this significant public health need. While advances in vaccine technologies have led to a recent resurgence in RSV vaccine development, the immune correlates of protection against RSV and the immunology of vaccine-associated enhanced respiratory disease (ERD) remain poorly understood...
September 22, 2016: Vaccine
https://www.readbyqxmd.com/read/27554839/determinants-of-host-susceptibility-to-murine-respiratory-syncytial-virus-rsv-disease-identify-a-role-for-the-innate-immunity-scavenger-receptor-marco-gene-in-human-infants
#18
Monica High, Hye-Youn Cho, Jacqui Marzec, Tim Wiltshire, Kirsten C Verhein, Mauricio T Caballero, Patricio L Acosta, Jonathan Ciencewicki, Zackary R McCaw, Lester Kobzik, Laura Miller-DeGraff, Wes Gladwell, David B Peden, M Elina Serra, Min Shi, Clarice Weinberg, Oscar Suzuki, Xuting Wang, Douglas A Bell, Fernando P Polack, Steven R Kleeberger
BACKGROUND: Respiratory syncytial virus (RSV) is the global leading cause of lower respiratory tract infection in infants. Nearly 30% of all infected infants develop severe disease including bronchiolitis, but susceptibility mechanisms remain unclear. METHODS: We infected a panel of 30 inbred strains of mice with RSV and measured changes in lung disease parameters 1 and 5days post-infection and they were used in genome-wide association (GWA) studies to identify quantitative trait loci (QTL) and susceptibility gene candidates...
September 2016: EBioMedicine
https://www.readbyqxmd.com/read/27553073/rsv-n-nanorings-fused-to-palivizumab-targeted-neutralizing-epitope-as-a-nanoparticle-rsv-vaccine
#19
Pierre-Louis Hervé, Charlotte Deloizy, Delphyne Descamps, Marie-Anne Rameix-Welti, Jenna Fix, Jason S McLellan, Jean-François Eléouët, Sabine Riffault
Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections in children, yet no vaccine is available. The sole licensed preventive treatment against RSV is composed of a monoclonal neutralizing antibody (palivizumab), which targets a conformational epitope located on the fusion protein (F). Palivizumab reduces the burden of bronchiolitis but does not prevent infection. Thus, the development of RSV vaccines remains a priority. We previously evaluated nanorings formed by RSV nucleoprotein (N) as an RSV vaccine, as well as an immunostimulatory carrier for heterologous antigens...
August 20, 2016: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/27464687/secretory-expression-and-purification-of-respiratory-syncytial-virus-g-and-f-proteins-in-human-cells
#20
Samadhan J Jadhao, Larry J Anderson
Respiratory syncytial virus (RSV) is one of the leading causes of range of symptoms from mild upper to serious lower respiratory virus infections in infants, immunocompromised individuals, and the elderly. Despite many decades of research and development, a licensed RSV vaccine is not available for use in human. Since the RSV F and G proteins induce neutralizing antibodies and confer protection from infection, they are important for understanding disease and for developing vaccines and access to purified, expressed proteins is important to RSV research and diagnostics...
2016: Methods in Molecular Biology
keyword
keyword
66261
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"